TP53 and cancer: Our preliminary screening of TP analogues 187, 197 and 421 demonstrated cytotoxicity in a panel of cancer cell lines of varied origin and cytogenetic attributes, inhibition of colony formation at submicromolar concentrations and cell cycle arrest independent of p53 competence.